Insider Trading Activity CytomX Therapeutics, Inc. (NASDAQ:CTMX) – CFO Sold 2,500 shares of Stock

ME Staff
-
0

Insider Trading Activity For CytomX Therapeutics, Inc. (NASDAQ:CTMX)

Debanjan Ray , CFO of CytomX Therapeutics, Inc. (NASDAQ:CTMX) reportedly Sold 2,500 shares of the company’s stock at an average price of 15 for a total transaction amount of $37,500.00 SEC Form

Insider Trading History For CytomX Therapeutics, Inc. (NASDAQ:CTMX)

  • On 10/14/2015 James E Flynn, Insider, bought 625,000 with an average share price of $12.00 per share and the total transaction amounting to $7,500,000.00.View SEC Filing
  • On 10/14/2015 Frederick W Gluck, Director, bought 15,000 with an average share price of $12.00 per share and the total transaction amounting to $180,000.00.View SEC Filing
  • On 10/14/2015 Cynthia J Ladd, VP, bought 3,000 with an average share price of $12.00 per share and the total transaction amounting to $36,000.00.View SEC Filing
  • On 5/20/2016 Ix L.P. Canaan, Director, sold 8,687 with an average share price of $10.10 per share and the total transaction amounting to $87,738.70.View SEC Filing
  • On 5/24/2016 Ix L.P. Canaan, Director, sold 13,253 with an average share price of $10.09 per share and the total transaction amounting to $133,722.77.View SEC Filing
  • On 5/26/2016 Timothy M Shannon, Director, sold 51,343 with an average share price of $10.34 per share and the total transaction amounting to $530,886.62.View SEC Filing
  • On 5/27/2016 Ix L.P. Canaan, Director, sold 25,082 with an average share price of $10.60 per share and the total transaction amounting to $265,869.20.View SEC Filing

    • Analyst Ratings For CytomX Therapeutics, Inc. (NASDAQ:CTMX)
    These are 1 Sell Rating, 2 Hold Ratings, 5 Buy Ratings .
    The current consensus rating for CytomX Therapeutics, Inc. (NASDAQ:CTMX) is Buy (Score: 2.50) with a consensus target price of $27.75 , a potential (100.36% upside)

    Analyst Ratings History For CytomX Therapeutics, Inc. (NASDAQ:CTMX)

    • On 3/1/2017 Nomura Initiated Coverage of rating Buy
    • On 3/4/2017 Oppenheimer Holdings, Inc. Reiterated Rating Hold
    • On 3/20/2017 Instinet Boost Price Target of rating Sell with a price target of $21.00 to $32.00
    • On 5/8/2017 HC Wainwright Reiterated Rating Buy
    • On 6/6/2017 Jefferies Group LLC Reiterated Rating Buy with a price target of $25.00
    • On 8/8/2017 Cowen and Company Reiterated Rating Buy
    • On 8/8/2017 Cann Reiterated Rating Hold

    Recent Trading Activity for CytomX Therapeutics, Inc. (NASDAQ:CTMX)
    Shares of CytomX Therapeutics, Inc. closed the previous trading session at 13.90 up +0.05 0.32% with 271,362 shares trading hands.